Bicycle Therapeutics PLC (BCYC)
21.38
-0.80
(-3.63%)
USD |
NASDAQ |
May 17, 16:00
21.38
0.00 (0.00%)
After-Hours: 18:58
Bicycle Therapeutics Enterprise Value: 418.27M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 418.27M |
| May 15, 2024 | 425.12M |
| May 14, 2024 | 405.70M |
| May 13, 2024 | 433.11M |
| May 10, 2024 | 445.30M |
| May 09, 2024 | 471.57M |
| May 08, 2024 | 473.09M |
| May 07, 2024 | 452.53M |
| May 06, 2024 | 460.91M |
| May 03, 2024 | 509.64M |
| May 02, 2024 | 513.83M |
| May 01, 2024 | 495.17M |
| April 30, 2024 | 466.62M |
| April 29, 2024 | 465.10M |
| April 26, 2024 | 436.80M |
| April 25, 2024 | 428.83M |
| April 24, 2024 | 434.52M |
| April 23, 2024 | 434.90M |
| April 22, 2024 | 430.73M |
| April 19, 2024 | 464.14M |
| April 18, 2024 | 503.62M |
| April 17, 2024 | 402.25M |
| April 16, 2024 | 406.43M |
| April 15, 2024 | 402.25M |
| April 12, 2024 | 420.48M |
| Date | Value |
|---|---|
| April 11, 2024 | 428.07M |
| April 10, 2024 | 446.67M |
| April 09, 2024 | 449.71M |
| April 08, 2024 | 445.53M |
| April 05, 2024 | 435.88M |
| April 04, 2024 | 431.33M |
| April 03, 2024 | 458.26M |
| April 02, 2024 | 473.81M |
| April 01, 2024 | 493.53M |
| March 31, 2024 | 518.18M |
| March 28, 2024 | 447.49M |
| March 27, 2024 | 434.24M |
| March 26, 2024 | 433.48M |
| March 25, 2024 | 467.57M |
| March 22, 2024 | 469.84M |
| March 21, 2024 | 483.48M |
| March 20, 2024 | 474.39M |
| March 19, 2024 | 434.24M |
| March 18, 2024 | 417.95M |
| March 15, 2024 | 404.31M |
| March 14, 2024 | 373.25M |
| March 13, 2024 | 472.12M |
| March 12, 2024 | 452.80M |
| March 11, 2024 | 400.90M |
| March 08, 2024 | 464.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-40.24M
Minimum
Nov 10 2023
1.568B
Maximum
Nov 15 2021
408.17M
Average
358.34M
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -2.169M |
| NuCana PLC | -14.18M |
| TC BioPharm (Holdings) PLC | 0.5053M |
| Adaptimmune Therapeutics PLC | 149.25M |
| Verona Pharma PLC | 876.92M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.56M |
| Revenue (Quarterly) | 19.53M |
| Total Expenses (Quarterly) | 51.32M |
| EPS Diluted (Quarterly) | -0.62 |
| Profit Margin (Quarterly) | -136.0% |
| Earnings Yield | -20.82% |
| Normalized Earnings Yield | -20.83 |